Assessment of heparin anticoagulation: comparison of two commercially available methods Hanne I Flom-Halvorsen, PhD, Eivind Øvrum, MD, PhD, Michel Abdelnoor,

Slides:

Advertisements

Similar presentations

The effect of cardiotomy suction on the brain injury marker S100β after cardiopulmonary bypass Russell E Anderson, MD, PhD, Lars-Olof Hansson, MD, PhD,

Advertisements

Relative Changes in Cerebral Blood Flow During Cardiac Operations Using Xenon-133 Clearance Versus Transcranial Doppler Sonography Uday H Trivedi, FRCS,

Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent.

Heparin-coated cardiopulmonary bypass equipment. II

Risk Index for Postoperative Acute Kidney Injury After Valvular Surgery Using Cardiopulmonary Bypass Takashi Yamauchi, MD, PhD, Shigeru Miyagawa, MD,

Leena Khaitan, MD, Francis P Sutter, Scott M Goldman, MD

Reduction of the Inflammatory Response in Patients Undergoing Minimally Invasive Coronary Artery Bypass Grafting Y.John Gu, Massimo A Mariani, Willem.

The Myocardial Protective Effects of a Moderate-Potassium Blood Cardioplegia in Pediatric Cardiac Surgery: A Randomized Controlled Trial Yang Liu, MD,

Relative Changes in Cerebral Blood Flow During Cardiac Operations Using Xenon-133 Clearance Versus Transcranial Doppler Sonography Uday H Trivedi, FRCS,

A Closed Perfusion System With Heparin Coating and Centrifugal Pump Improves Cardiopulmonary Bypass Biocompatibility in Elderly Patients Lena Lindholm,

Anaerobic Metabolism During Cardiopulmonary Bypass: Predictive Value of Carbon Dioxide Derived Parameters Marco Ranucci, MD, Giuseppe Isgrò, MD, Federica.

Tumor necrosis factor-α production in whole blood after cardiopulmonary bypass: Downregulation caused by circulating cytokine-inhibitory activities J.

Reduction of heparin dose is not beneficial to platelet function

P. W. Boonstra, MD, PhD, Y. J. Gu, MD, PhD, C. Akkerman, BSc, J

James L Zellner, MD, Scott B Kribbs, BS, B

Bashir M Matata, PhD, Andrzej W Sosnowski, MD, Manuel Galiñanes

Is kidney function altered by the duration of cardiopulmonary bypass?

Emergency Coronary Artery Bypass Grafting Can Be Performed Safely Without Cardiopulmonary Bypass in Selected Patients Faraz Kerendi, MD, John D. Puskas,

Changes in the effect of propofol in response to altered plasma protein binding during normothermic cardiopulmonary bypass E Takizawa, H Hiraoka, D Takizawa,

Steven R. Gundry, MD, Matthew A. Romano, MD, O

Effects of Depletion of Leukocytes and Platelets on Cardiac Dysfunction After Cardiopulmonary Bypass Yukio Chiba, Kouichi Morioka, Ryusuke Muraoka, Akio.

Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization Hiroshi Kumano, MD, PhD, Shigefumi Suehiro, MD, PhD, Koji.

Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only Thierry P Carrel, MD, Mike Schwanda, MD,

Susanne Lison, MD, Michael Spannagl, MD, PhD, Wulf Dietrich, MD, PhD

Definition of postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass: One size doesn't fit all David Faraoni, MD,

Effect of Heparin Loading During Congenital Heart Operation on Thrombin Generation and Blood Loss Sophronia O Turner-Gomes, MB, ChB, Evan P Nitschmann,

Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass Martin Strüber, MD, Jochen T Cremer, MD, Bernhard.

Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery John L Francis, PhD, George J Palmer, MD, Rebecca Moroose,

Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass Alvise Bernabei,

Hypogammaglobulinemia after cardiopulmonary bypass in infants

Saving Lives Is More Important Than Abstract Moral Concerns: Financial Incentives Should Be Used to Increase Organ Donation Benjamin Hippen, MD, Lainie.

Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent.

Anne H Kuitunen, MD, Lasse J Heikkilä, MD, Markku T Salmenperä, MD

Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements G.J. Despotis, MD, J.H. Joist,

Coronary surgery without cardiotomy suction and autotransfusion reduces the postoperative systemic inflammatory response Martin Westerberg, MD, Anders.

Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity Cedric Manlhiot, PhD, Colleen.

Effect of cerebral embolization on regional autoregulation during cardiopulmonary bypass in dogs Hulya Sungurtekin, MD, Umar S Boston, MD, Thomas A Orszulak,

Benjamin C. Sun, MD, Timothy A. Dickinson, CCP, Eric A

Infant cardiopulmonary bypass: a procoagulant state

Editorial Board, January 2010

Bradford B. Smith, MD, Matthew A

Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery Julio C Vasquez, MD, Anna Vichiendilokkul, PharmD, Syed Mahmood, MD,

Individualized heparin and protamine management in infants and children undergoing cardiac operations Massimiliano Codispoti, MD, Christopher A Ludlam,

Safety and efficacy of a heparin removal device: a prospective randomized preclinical outcomes study Joseph B Zwischenberger, MD, Weike Tao, MD, Donald.

Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary.

Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass Nobuhiko Hayashida, MD, PhD, Hiroshi Tomoeda, MD, Takeshi Oda, MD,

No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits Christian Olsson, MD, Agneta Siegbahn, MD, PhD,

Off-Pump Coronary Artery Bypass Disproportionately Benefits High-Risk Patients John D. Puskas, MD, Vinod H. Thourani, MD, Patrick Kilgo, MS, William Cooper,

Hans-Joachim Schäfers, MD, PhD, Diana Aicher, MD, Frank Langer, MD

Is the kaolin or celite activated clotting time affected by tranexamic acid? J.F.Matthias Bechtel, MD, Joachim Prosch, Hans-Hinrich Sievers, MD, Claus.

Stephanie B. Clayton, PharmD, Jeffrey R. Acsell, CCP, Arthur J

Time course of proinflammatory and anti-inflammatory responses after cardiac operation: monocyte HLA-DR expression Y.John Gu, MD, PhD, Willem van Oeveren,

Olaf Reinhartz, MD, Anil M DeSilva, MD, Frank L Hanley, MD

Neurocognitive Function and Cerebral Emboli: Randomized Study of On-Pump Versus Off-Pump Coronary Artery Bypass Surgery Reza Motallebzadeh, MRCS, J.

Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair Greg Stratmann, MD, PhD, Isobel A Russell,

Aprotinin Enhances the Endogenous Release of Interleukin-10 After Cardiac Operations Gary E Hill, Robert P Diego, Alfred H Stammers, Suzanne M Huffman,

Randomized Controlled Trial of Pericardial Blood Processing With a Cell-Saving Device on Neurologic Markers in Elderly Patients Undergoing Coronary Artery.

Pulmonary Embolectomy for Acute Massive Pulmonary Embolism

Neal S Goldstein, MD The Annals of Thoracic Surgery

Fraser D. Rubens, MD, MS, Gilbert Lavalee, Marc A

Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient

Increased neutrophil priming and sensitization before commencing cardiopulmonary bypass in cardiac surgical patients Y.John Gu, MD, PhD, Pieter Schoen,

Adnan Cobanoglu, MD, Jess M Schultz, MD The Annals of Thoracic Surgery

Cerebral microemboli during cardiopulmonary bypass: increased emboli during perfusionist interventions Ruth L Taylor, MSc, Michael A Borger, MD, Richard.

An Assay to Monitor Bivalirudin Levels on Cardiopulmonary Bypass

Influence of High- and Low-Dose Aprotinin on Activation of Hemostasis in Open Heart Operations Wulf Dietrich, Karl Schöpf, Michael Spannagl, Marianne.

Safety of low hematocrits during cardiopulmonary bypass

Y.John Gu, MD, PhD, Piet W. Boonstra, MD, PhD, Willem van Oeveren, PhD

Recombinant hirudin for extended aortic surgery in patients with heparin-induced thrombocytopenia Matthias Bauer, MD, Andreas Koster, MD, Miralem Pasic,

A randomized trial of antithrombin concentrate for treatment of heparin resistance Mathew R Williams, MD, Alyssa B D’Ambra, BA, James R Beck, Talia B.

Presentation transcript:

Assessment of heparin anticoagulation: comparison of two commercially available methods Hanne I Flom-Halvorsen, PhD, Eivind Øvrum, MD, PhD, Michel Abdelnoor, PhD, Stine Bjørnsen, Frank Brosstad, MD, PhD The Annals of Thoracic Surgery Volume 67, Issue 4, Pages 1012-1016 (April 1999) DOI: 10.1016/S0003-4975(99)00217-9

Fig 1 The relationship between the clotting time in seconds of activated clotting time (ACT) and thrombolytic assessment system heparin management test (TAS HMT) methods and the plasma heparin concentration (IU/mL) measured by anti-FXa assay in ten patients who had cardiopulmonary bypass (CPB). The data are presented as mean values. The Annals of Thoracic Surgery 1999 67, 1012-1016DOI: (10.1016/S0003-4975(99)00217-9)

Fig 2 Ex vivo study. (A) Regression line between the clotting time (in seconds) of whole blood activated clotting time (ACT). (B) Thrombolytic assessment system heparin management test (TAS HMT) and plasma heparin concentration (IU/mL) measured in samples from ten patients who had cardiopulmonary bypass. The data are corrected for their respective baseline values, and the mean values of the double determinations are used. The Annals of Thoracic Surgery 1999 67, 1012-1016DOI: (10.1016/S0003-4975(99)00217-9)

Fig 3 In vitro study. (A) Regression line between the activated clotting time (ACT). (B) thrombolytic assessment system heparin management test (TAS HMT) seconds and measured plasma heparin concentration (IU/mL) in samples from donor whole-blood spiked with known amounts of heparin. The data are corrected for their baseline values and presented as mean values. The Annals of Thoracic Surgery 1999 67, 1012-1016DOI: (10.1016/S0003-4975(99)00217-9)